MedTrace Logo

Synthetic CBD as a Therapy for COVID-19

NCT04686539 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-09-28

No results posted yet for this study

Summary

The study aim to test proof of concept of CBD treatment for efficacy and safety in patients suffering with mild COVID-19 infection. The CBD will be delivered via oil droplets not containing THC, compared to placebo.

Conditions

  • Covid19
  • CBD

Interventions

DRUG

CBD

CBD oil not containing THC, to be administered sub-lingual.

DRUG

Placebo

Placebo Oil

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Howard Amital, MD, MHA · Head of Internal Medicine ward "B", Sheba Health Center, Tel Hashomer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-20
Primary Completion
2021-11-30
Completion
2022-01-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04686539 on ClinicalTrials.gov